Trial Profile
A retrospective study investigating potential biomarkers to predict therapeutic effect of ramucirumab in combination with paclitaxel as a second line therpay in Korean patients with recurrent/metastatic gastric cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2016
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 12 Dec 2016 New trial record